Celsion Corporation
(Public, NASDAQ:CLSN) Watch this stockFind more results for
Celsion
Advertisement
Events
Nov 10, 2009
Q3 2009 Earnings Release
Nov 10, 2009
Q3 2009 Earnings Conference Call
Sep 9, 2009
Rodman & Renshaw Annual Global Investment Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | - | -471.44% |
| Operating margin | - | -461.96% |
| EBITD margin | - | -459.20% |
| Return on average assets | -100.93% | -37.58% |
| Return on average equity | -131.31% | -46.79% |
| Employees | 17 | - |
Address
10220-L Old Columbia Road
Columbia, MD 21046
United States - Map
+1-410-2905390 (Phone)
+1-410-2905394 (Fax)
Columbia, MD 21046
United States - Map
+1-410-2905390 (Phone)
+1-410-2905394 (Fax)
Website links
Company website:
http://www.celsion.com
http://www.celsion.com
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Celsion Corporation discussions
View all discussions »Description
Celsion Corporation (Celsion) is an oncology drug development company focused on developing drugs for the treatment of various cancer indications. The Company’s product ThermoDox is evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer (RCW). ThermoDox is a liposomal encapsulation of doxorubicin, an oncology drug for the treatment of a range of cancers.
Officers and directors
| Max E. Link Ph.D. | Chairman of the Board | |
| Michael H. Tardugno | President, Chief Executive Officer, Director | |
| Sean F. Moran | Chief Financial Officer, Senior Vice President, Chief Accounting Officer | |
| Nicholas Borys MD. | Vice President, Chief Medical Officer | |
| Gary W. Pace Ph.D. | Director | |
| Gregory L. Weaver | Director | |
| Pok Yu Chow | Director |